Cystathionine γ-Lyase Identified as a Key Regulator of Memory and Learning
January 1, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Laverdia-CA1
Synonyms :
verdinexor
Class :
Antineoplastic, Nuclear export inhibitor
Brand Name :
Laverdia-CA1
Synonyms :
verdinexor
Class :
Antineoplastic, Nuclear export inhibitor
Dosage Forms & Strengths
Tablet
2.5 mg
10 mg
50 mg
Canine Lymphorma (off-label)
It's recommended for treating canine lymphoma
Provide the dog with a meal just before administering this medication
Use protective disposable chemotherapy-resistant gloves while handling this drug
Initiate the administration of medication at an initial dosage of 1.25 mg per kg orally twice a week (for example, on Monday and Thursday or Tuesday and Friday), ensuring a minimum of 72 hours :
Dose Adjustments
Limited data is available
It is used as Veterinary Medicine (Only dogs) and also as investigational drug
Canine Lymphorma (off-label)
It's recommended for treating canine lymphoma
Provide the dog with a meal just before administering this medication
Use protective disposable chemotherapy-resistant gloves while handling this drug
Initiate the administration of medication at an initial dosage of 1.25 mg per kg orally twice a week (for example, on Monday and Thursday or Tuesday and Friday), ensuring a minimum of 72 hours :
It is used as Veterinary Medicine (Only dogs) and also as investigational drug
Actions and Spectrum:
Actions:
LAVERDIA-CA1, a selective inhibitor of nuclear export, inhibits chromosome region maintenance 1 (CRM1).
Frequency defined
>10%
Bilirubinuria
Polydipsia
Elevated liver enzymes
Edema
Proteinuria
Thrombocytopenia
Hematuria
Anemia
Elevated BUN
Hyperphosphatemia
Monocytosis
Lymphopenia
Partial thromboplastin time
Hypercalcemia
Leukocytosis
Neutropenia
>10%
Lymphadenitis
Protein losing nephropathy
Bruising
Corneal opacity
Erythema
Nasal discharge
Hepatomegaly
Epistaxis
Elevated bilirubin
Heart block
Hypoalbuminemia
Arrythmias
Black Box Warning:
Do not use in humans. Keep away from children. Avoid contact with Laverdia-CA1. Children should not touch treated dogs’ waste or saliva.
Contraindication/Caution: (Not for human use)
Contraindications
Cautions
Pregnancy/Lactation
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of drug in breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
<b>Category B: There was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: Adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
Verdinexor inhibits Exportin 1, reducing canine tumor cell growth, and inhibits influenza virus replication both in vivo and in vitro.
Pharmacodynamics:
Verdinexor blocks CRM1, stopping nuclear export, especially in damaged cells like tumors, by trapping Growth Regulatory Proteins and Tumor Suppressor Proteins inside the nucleus.
Pharmacokinetics: (dogs)
Absorption
Peak effect can be reached between 1.1 & 2.5 hours.
Excretion and Elimination
The half-life is 2-4 hours
Administration:
Give the dog a meal before giving the medication orally.
Patient information leaflet
Generic Name: verdinexor
Pronounced: ver-dih-NECK-sor
Why do we use verdinexor?
Verdinexor is used in cancer treatment that targets exportin-1, keeping tumor-suppressor proteins inside cells to regulate cell growth & inhibit cancer cell proliferation. Ongoing research is exploring its effectiveness and potential for broader cancer therapy applications.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
